documentation of the who had an outpatient visit patients diagnosed with HIV to occurrence of an HIV during the measurement period the start of the measurement period test between their 15th and 66th birthdays and before the end of the measurement period APPENDIX B: MEASURE RATIONALES Legend for Measure Rationales MUC ID: Gives users an identifier to refer to a measure. Measure Title: Refers to the title of the measure. Rationale: Refers to the rationale for the measure, the peer-reviewed evidence justifying the measure, and/or the impact the measure is anticipated to achieve. Measure Rationales MUC ID Measure Title Rationale Continuity of In this section, first we summarize the evidence from the systematic reviews and meta-analyses cited by the Pharmacotherapy 2015 clinical practice guideline for the management of substance use disorders” that support the “VA/DoD for Opioid Use recommendations related to pharmacotherapy for treatment of opioid use disorder. Following that, we Disorder present evidence in support of the measure definition: using a minimum of 6 months’ duration of pharmacotherapy, and no gaps of more than seven days.
documentation of the occurrence of an HIV test between their 15th and 66th birthdays and before the end of the measurement period who had an outpatient visit during the measurement period patients diagnosed with HIV to the start of the measurement period APPENDIX B: MEASURE RATIONALES Legend for Measure Rationales MUC ID: Gives users an identifier to refer to a measure. Measure Title: Refers to the title of the measure. Rationale: Refers to the rationale for the measure, the peer-reviewed evidence justifying the measure, and/or the impact the measure is anticipated to achieve. Measure Rationales MUC ID Measure Title Rationale Continuity of Pharmacotherapy for Opioid Use Disorder In this section, first we summarize the evidence from the systematic reviews and meta-analyses cited by the 2015 “VA/DoD clinical practice guideline for the management of substance use disorders” that support the recommendations related to pharmacotherapy for treatment of opioid use disorder. Following that, we present evidence in support of the measure definition: using a minimum of 6 months’ duration of pharmacotherapy, and no gaps of more than seven days.